Skip to main content

Specialty Pharmacy

  • Diplomat dispensing Mavyret

    FLINT, Mich. — Diplomat Pharmacy is dispensing a newly approved treatment for chronic hepatitis C. The company on Friday announced that it is now dispensing AbbVie’s Mavyret (glecaprevir and pibrentasvir) tablets.

    The drug is indicated to treat patients with all major genotypes of chronic hepatitis C infection with cirrhosis or with compensated cirrhosis. It also is also indicated for adults with Genotype 1 infection who previously have been treated with a regimen containing an NS5A inhibitor or an NS3/4A protease inhibitor (but not both).

  • FDA approves Pfizer’s leukemia drug Besponsa

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug from Pfizer, Besponsa (inotuzumab ozogamicin). The drug is indicated to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, or ALL.

  • Lynzparza’s new tablet formulation gets FDA approval, expanded indication

    WILMINGTON, Del. — AstaZeneca and Merck’s Lynzparza (olaparib) tablets were approved by the Food and Drug Administration, as well as given an expanded indication by the regulatory agency.

  • Future Trends: Integration, chronic care lie ahead for pharmacy

    What will retail pharmacy look like in 2027? Predicting the future is always iffy, but it’s certain that it will involve a lot of “C” words. Among them are connectivity; computing or, more accurately, the use of supercomputers in advanced diagnosis, medication therapy and drug development; collaboration; clinical care; and cost-saving imperatives.

  • Diplomat now dispensing prescription-free naloxone

    FLINT, Mich. — Diplomat Pharmacy has joined the ranks of pharmacy chains providing naloxone to its patients without requiring a prescription. The company on Tuesday announced that it would be offering the opioid overdose antidote at its Flint retail pharmacy.

    “Protecting the health and safety of our patients is what we do,” Diplomat EVP operations Gary Rice. “We are committed to providing access to lifesaving medication like naloxone in the communities we serve.”

  • NASP launches resource site about DIR Fees

    WASHINGTON — The National Association of Specialty Pharmacy on Monday launched a new resource hub built around educating patients and pharmacists about the impact the organization sees direct and indirect remuneration, or DIR, fees having on specialty pharmacies and the patients they serve.

  • Makers of first ALS drug in 22 years announce availability

    JERSEY CITY, N.J. — The first drug for ALS approved in 22 years is now available. Mitsubishi Tanabe Pharma America this week announced the introduction of its Radicava (edaravone), an intravenous treatment for ALS that the Food and Drug Administration approved on May 5.

  • Mylan launches 3 HIV generics in Canada

    HERTFORDSHIRE, England, PITTSBURGH and TORONTO — Mylan has launched three generics for treating HIV in Canada. Among the three launches is the company’s generic of Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate, 200 mg/300 mg), as well as generics of Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate, 600 mg/200 mg/300 mg) and Viread (tenofovir disoproxil, 300 mg).

X
This ad will auto-close in 10 seconds